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Background. Neoadjuvant chemoradiotherapy (nCRT) followed by curative surgery in locally advanced rectal cancer (LARC)
improves pelvic disease control. Survival improvement is achieved only if pathological response occurs. Mandard tumor regression
grade (TRG) proved to be a valid system to measure nCRT response. Potential predictive factors for Mandard response are
analyzed.Materials andMethods. 167 patients with LARCwere treatedwith nCRT and curative surgery. Tumor biopsies and surgical
specimens were reviewed and analyzed regarding mitotic count, necrosis, desmoplastic reaction, and inflammatory infiltration
grade. Surgical specimens were classified according to Mandard TRG. The patients were divided as “good responders” (Mandard
TRG1-2) and “bad responders” (Mandard TRG3-5). According to results from our previous data, good responders have better
prognosis than bad responders.We examined predictive factors forMandard response and performed statistical analysis.Results. In
univariate analysis, distance from anal verge and ten other postoperative variables relatedwith nCRT tumor response had predictive
value for Mandard response. In multivariable analysis only mitotic count, necrosis, and differentiation grade in surgical specimen
had predictive value. Conclusions. There is a lack of clinical and pathological preoperative variables able to predict Mandard
response. Only postoperative pathological parameters related with nCRT response have predictive value.
1. Introduction
Neoadjuvant chemoradiotherapy (CRT) followed by total
mesorectum excision (TME) surgery and systemic chemo-
therapy remains the standard of care for locally advanced
rectal cancer (LARC), but only a few patients benefit from
this treatment modality. Sauer et al. [1] reported a per-
sistent significant improvement of preoperative CRT ver-
sus postoperative CRT on local control, although without
overall survival improvement, which is only achieved in
situations of good or complete pathological response to CRT
[2, 3]. Chemoradiation induces tumor downstaging effect,
which increases the probability of a complete resection and
a sphincter- preserving surgery, benefiting local control.
However, some patients still develop distant and/or local
recurrence that compromise survival, particularly those with
poor pathological tumor response. The histological response
to preoperative CRT has been reported in several studies
to be closely related to oncologic outcomes [2, 4–7]. A
complete pathologic response (pCR), which is characterized
by sterilization of all tumor cells, leads to excellent prognosis
and is observed in approximately 10% to 30% of cases [8].
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The remaining patients exhibit a spectrumof residual disease,
ranging frommicroscopic tumor cell foci on a background of
radiation-induced fibrosis to no response at all [9].The prog-
nostic relevance of pathological tumor response according to
several standard grading criteria has been studied extensively
[4, 10–13]. In our previous study, the Mandard system proved
to be a good determinant of outcome, when cases were
grouped into TRG1+2 (good responders) and TRG3+4+5
(bad responders). This methodology proved superior com-
pared to division in groups of ypCR (TRG1) versus all
other (TRG2–5) regarding disease-free survival (DFS) and
overall survival (OS) [14]. For this reason it would be of
great value to predict nCRT-induced histologic regression
and tumor shrinkage. The ability to predict the response,
either before treatment or during its early stages, could
spare “bad responders” patients the expense and stress of
undergoing treatment fromwhich they will derive no benefit.
Instead, these patientswould be candidates formore intensive
treatment strategies. Identifying “bad responders” only in
posttreatment may also be an indicator for a different and
more intensive adjuvant therapy. Nowadays, individualizing
the treatment approach in LARC is a demanding goal to
achieve.
The present study aims to analyze predictive factors of
Mandard tumor response, trying to identify and characterize
the “good” and the “bad responders,” comparing classic
histological data obtained from diagnostic biopsies with his-
tological alterations from surgical specimens after treatment.
2. Materials and Methods
2.1. Patient Population. A single-institution database was
queried for consecutive patients with LARC, biopsy-proven
rectal adenocarcinoma, who underwent nCRT followed by
elective radical surgery with TME with curative intent
between January 1, 2003, and December 31, 2013.
Admission Criteria. Patients with rectal cancers located at less
than 12 cm of distance from the anal verge and clinical stages
cT2N+M0 or cT3/4 N0/+M0 are included.
Exclusion Criteria. Patients with other diagnosed neoplasia,
short course RT, yp stage IV, R1/R2 surgery, and death within
60-day postoperative time are excluded.
All patients receiving nCRT who were operated within
8 weeks after radiotherapy conclusion were included in
this analysis. Patients receiving short-course radiation were
excluded since no downstaging occurs when immediate
surgery is carried out.
Staging included rigid proctoscopy, total colonoscopy,
chest, abdominal, and pelvic CT scan, endorectal ultrasound
(ERUS), pelvic magnetic resonance image (MRI) (since
2008), and carcinoembryonic antigen (CEA) serum levels.
Diagnostic pretreatment paraffin-embedded biopsies
of 152 patients (91%) were available and reviewed by an
independent element. All of them were characterized
in terms of grade, mitotic index (for 10 fields), necrosis
grade (scarce/moderate/marked), inflammatory reaction
(scarce/moderate/marked), and desmoplastic infiltration
(scarce, moderate, and marked). Tumor biopsy samples
classification, including grade, were obtained on worst areas
whenever available material contained several areas with
neoplasia.
Neoadjuvant CRT protocol included total irradiation of
50.4Gy in 28 fractions and 5-fluorouracil by infusion pump.
Radical surgery consisted mainly in sphincter saving
rectal resection (SSRE) or abdominoperineal resection (APR)
both with TME. Regarding operative procedure selection,
we considered the distance of the lesion to the anus, the
comorbidities of the patient, and the condition of the anal
sphincter.
The number of samples taken from the resected speci-
mens was variable, with a mean of 6 paraffin blocks per case.
The methodology used was the following:
(1) Five samples were from the area with macroscopic
lesion (assuming it exists), that is, the same as
dealing with a specimen from a patient who has
not received neoadjuvant therapy. These included
the closest macroscopic approach of the macroscopic
lesion to the peritoneal surface and/or the mesorectal
excision plane, as appropriate.
(2) If no viable tumour was identified within the initial
5 blocks, the whole of the remainder of any macro-
scopic lesion in additional blocks was included.
(3) If no viable tumour was identified within the initial
or extra blocks, another three further levels from all
of these blocks were taken. If no viable tumour was
identified in these sections then complete histological
tumour regression was assumed.
All obtained slides were seen and reviewed by the same
pathologist. Items observed and registered in the biopsies
were subsequently analyzed in the resected specimen and the
same criteria adopted.
Standard pathologic tumor staging of the resected speci-
men was performed in accordance with the guidelines of the
American Joint Committee on Cancer (AJCC). Circumfer-
ential resection margin (CRM) was scored as positive when
cancer cells were within 1mm of the margin. Evidence of
ypCR was defined as an absence of viable adenocarcinoma
in the surgical specimen or the presence of lakes of mucus
without tumor cells.
The histology of all surgical specimens was reviewed and
confirmed by an independent element and were classified
based on Mandard tumor regression grading system.
Patients were divided in two groups according to Man-
dard TRG system: good responders were defined asMandard
TRG1 or TRG2; bad responders were defined as Mandard
TRG3, TRG4, or TRG5 (Figure 1).
Both groups (good responders versus bad responders)
were used to evaluate outcome results. Operated patients
were subjected to adjuvant chemotherapy protocol for 6
months performed preferably with 5-fluorouracil (5-FU) or
a combination 5-FU and oxaliplatinum.
Disease recurrence was evaluated according to location:
locoregional (LR), systemic (DR), or mixed.
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TRG1
TRG1
TRG2
TRG2
No viable cancer cells, complete response
Single cells or small groups of cancer cells
Residual cancer outgrown by fibrosis
Significant fibrosis outgrown by cancer
No fibrosis with extensive residual cancer
TRG3
TRG3
TRG4
TRG4
TRG5
TRG5
(TRG1 + TRG2)
Mandard good responders
Mandard bad responders
(TRG3 + TRG4 + TRG5)
Figure 1: Mandard system.
None of the patients were lost for follow-up.
All surviving patients were observed and their current
status was confirmed.
Clinical nodal staging may present some inaccuracies;
consequently, downstaging evaluation including N stage may
introduce some bias, so the term “downstaging” used to
describe the efficacy of treatment was defined specifically as
T stage downstaging.
Disease-free survival (DFS) was calculated from the date
of surgery to the date of progression (local and/or distant),
and overall survival (OS) was calculated from the first date of
treatment to the date of death or last follow-up.
2.2. Statistical Analysis. The survival function was estimated
using the Kaplan-Meier method. The difference in survival
rates between groups was tested for significance using the
log rank test. The significance of differences in proportions
was calculated with Chi-square test and the differences in
means with Student’s t-test. A logistic regression analysis
was used to assess the independent significance of factors
predictive of response, defined as “good” or “bad” responders
(TRG1-2/TRG3–5): age; gender; clinical stage; anal–tumor
distance; pretreatment CEA; biopsy specimen characteristics:
mitotic index, desmoplastic infiltration, inflammatory reac-
tion, and necrosis; CEA post-CRT; surgical procedure; sur-
gical morbidity; pathological stage; circumferential involve-
ment; tumor grade; tumor mitosis number; tumor desmo-
plastic infiltration; tumor inflammatory reaction; and tumor
necrosis in resected specimen were studied.
The statistical analysis was made with SPSS statistical
software (version 21.0 for Windows; SPSS Inc., Chicago, IL).
All statistical tests were conducted at a two-sided level of
significance of 0.05.
3. Results
3.1. Patient Population. Between January 2003 andDecember
2013, 186 consecutive patients with LARC were treated with
neoadjuvant CRT followed by TME surgery at one single
university hospital. We excluded 11 patients with positive
radial margin (R1 surgery), 4 patients with yp stage IV,
and four deaths within 60 days of postoperative period. In
the end, 167 patients were included in the present analysis.
Male : female ratio was 1.69 : 1. Median age was 64.6 years
(range, 29–83 years). Clinical parameters are summarized in
Table 1.
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Table 1: Clinical parameters.
Variable 𝑁 (%)
Age
Mean 64.62
Range (29–83)
Gender
Male 105 (62.9)
Female 62 (37.1)
Tumor length
<4 cm 41 (24.6)
≥4 cm and <6 cm 85 (50.8)
≥6 cm 41 (24.6)
Tumor circumference
≤1/3 27 (16.2)
>1/3 and ≤1/2 59 (35.3)
>1/2 and ≤2/3 39 (23.4)
>2/3 and ≤3/3 42 (25.1)
Distance from anal verge
>6 cm 81 (48.5)
≤6 cm 86 (51.5)
CEA pre-CRT
<5 116 (69.5)
≥5 44 (26.3)
Missing 7 (4.2)
cT stage
2-3 152 (91.0)
4 15 (9.0)
Clinical stage
II 76 (45.5)
III 91 (54.5)
CEA post-CRT
<5 141 (84.4)
≥5 14 (8.4)
Missing 12 (7.2)
Surgery procedure
AAR/SSO 107 (64.1)
AAP/others 60 (35.9)
Surgery
Open 129 (77.2)
Laparoscopic 38 (22.8)
Perioperative complications 42 (25.1)
Morbidity
Abdominal or pelvic abscess 16 (9.5)
Anastomose leak 3 (1.7)
Reoperation 6 (3.5)
Readmission 3 (1.7)
3.2. Biopsy Characteristics. The biopsy results are shown in
Table 2.
The mitotic index is the number of mitoses for 10 high-
powered fields and the cut-offwas chosen taking into account
the best ratio of sensitivity : specificity. If no 10 high-power
fields were present with neoplasia, the number of mitoses was
Table 2: Biopsies characteristics.
Variable 𝑁 (%)
Biopsy
Grade
1 46 (27.5)
2 98 (58.7)
3 8 (4.8)
Missing 15 (9.0)
Mucinous presence
No 145 (86.8)
Yes 7 (4.2)
Missing/not applied 15 (9.0)
Mitosis number
≤9.5 34 (20.4)
≥9.6 117 (70.0)
Missing/not applied 16 (9.6)
Inflammatory infiltrate
Scarce 33 (19.8)
Moderated 66 (39.5)
Marked 52 (31.1)
Missing/not applied 16 (9.6)
Desmoplastic reaction
Scarce 44 (26.3)
Moderated 80 (47.9)
Marked 27 (16.2)
Missing/not applied 16 (9.6)
Necrosis degree
Scarce 79 (47.3)
Moderated 40 (23.9)
Marked 32 (19.2)
Missing/not applied 16 (9.6)
counted in the number of observed fields, reducing the final
result to 10 fields.
3.3. Surgery. Sphincter saving rectal resection with anasto-
mosis (with or without protective ileostomy) was performed
on 107 patients (64.1%). Abdominoperineal resection was
performed on 53 patients, and seven patients were subjected
to proctectomy with definitive stoma. The perioperative
morbidity of the series was of 25,1% with 16 abdominal or
pelvic abscesses, 3 anastomotic leaks, 6 reoperations, and 3
readmissions.
3.4. Pathology. Stage distribution is shown in Table 3.
The average number of dissected lymph nodes in the
surgical specimen was 8.2 (range 0–22).
Circumferential resection margin >1mm was confirmed
in all 167 patients. Response to neoadjuvant therapy is
characterized in Table 3.
Downstaging and Final Pathologic Stage Classification. T stage
downstaging was observed in 67 patients (40.1%). Reduction
in T stage by one level was observed in 29 patients (17.4%) and
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Table 3: Pathological parameters.
Variable 𝑁 (%)
ypT stage
pT0-1 38 (22.8)
pT2–4 129 (77.2)
ypN stage
pN0 110 (65.9)
pN1-2 57 (34.1)
Pathological stage
0 58 (34.7)
II 58 (34.7)
III 51 (30.5)
T downstaging
Yes 67 (40.1)
No 100 (59.9)
Pathological TNM downstaging
Yes 95 (56.9)
No 72 (43.1)
CRM distance
>2mm 159 (95.2)
≤2 and >1mm 8 (4.8)
Mandard TRG
TRG1-2 (good responders) 85 (50.9)
TRG3–5 (bad responders) 82 (49.1)
Other characteristics of resected specimen
Grade
0 32 (19.2)
1 31 (18.6)
2 98 (58.7)
3 6 (3.6)
Mucinous presence
Yes 41 (24.5)
No 126 (75.4)
Inflammatory infiltrate
Scarce 60 (35.9)
Moderated 75 (44.9)
Marked 28 (16.8)
Missing 4 (2.4)
Desmoplastic reaction
Scarce 45 (26.9)
Moderated 64 (38.3)
Marked 51 (30.5)
Missing 7 (4.2)
Necrosis grade
Scarce 27 (16.2)
Moderated 38 (22.8)
Marked 99 (59.3)
Missing 3 (1.8)
Mitosis number
≤9.5 73 (43.7)
>9.5 68 (40.7)
Missing 26 (15.6)
Table 3: Continued.
Variable 𝑁 (%)
Lymphatic permeation
No 100 (59.9)
Yes 67 (40.1)
Vascular permeation
No 142 (85)
Yes 25 (15)
Perineural permeation
No 96 (57.5)
Yes 71 (42.5)
Distal margin
≥2 cm 108 (65.7)
<2 cm and ≥1 cm 59 (35.3)
by two or more levels in 38 patients (22.8%). Observations
indicating pathologic downstaging are given in Table 3.
Ninety-five (56.8%) patients presented pathologic stage one
or lower pathologic stage than initial clinical tumor stage.
Pathologic complete response (ypCR orMandard TRG1) was
confirmed in 31 patients (18.5%).
TRG Classification. The use of Mandard system allowed us to
define two groups as previously mentioned: good responders
(Mandard TRG1-2) and bad responders (Mandard TRG3–
5). Using Mandard system a good response to nCRT was
attributed to 85 patients (50.9%) and a bad response was
attributed to 82 patients (49.1%).
3.5. Clinical Outcome. Table 4 shows long term clinical
outcome, relapse of disease, and survival.
With a median follow-up of 59 months (range, 6–139
months), five-year overall survival was 74.6% and pelvic con-
trol was 95.8%. Seven patients (4.2%) developed pelvic recur-
rence (5 isolated and 2 with synchronous metastatic disease)
and 22 (12.6%) distant metastases alone. Mandard TRG3–5
(bad responders) is associated with adverse prognosis.
3.6. Predictive Factors of Mandard Response. A logistic
regression analysis was used to assess the independent signif-
icance of pre- and on-treatment variables as predictive factors
of Mandard good responders (TRG1-2). Table 5 shows the
11 variables with predictive value for Mandard response in
univariate analysis.
All were related with tumor downstaging and/or with
tumor CRT response except the tumor anal distance. The
other variables of Tables 1, 2, and 3 have no significant
predictive value.
The eleven variables were entered into the Cox-stepwise
likelihood ratio.The selection was based upon their statistical
significance in univariate analysis and their potential clinical
interaction. In the multivariate analysis, after adjustment for
the effects of the other variables, tumor with moderated or
poor differentiation grade, scarce or moderated necrosis, and
>9.5 mitosis number for 10 high-powered fields were more
likely to present a bad response (Table 6).
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Table 4: Clinical long term outcome (follow-upmedian: 59months;
range 6–139).
Variable
Overall disease recurrence 29 (17.3%)
Local 5 (3%)
Distant 22 (13.2%)
Local and distant 2 (1.1%)
Five-year overall survival 74.6% (se = 3.8%)
Five-year overall survival for “good
responders”∗
88.3% (se = 3.9%)
Five-year overall survival for “bad
responders”∗
58.3% (se = 6.5%)
∗
𝑝 < 0.001 (log rank test).
4. Discussion
Neoadjuvant CRT followed by curative surgery and adjuvant
chemotherapy is used in advanced rectal cancer and the
prognosis depends essentially on tumor response. This kind
of treatment allows a better pelvic disease control, but better
prognosis is achieved only in good responders [2].
The variety of tumor responses has increased the need
to find a useful predictive model for the response to CRT
in order to identify patients who will really benefit from this
multimodal treatment.
In our previous studies Mandard TRG system proved to
be fairly accurate, and patients division in good (TRG1-2)
and bad responders (TRG3–5) proved effective [10, 14].These
results have been confirmed by other groups [2, 12, 15, 16].
Based on those results it would be important to analyze
potential clinical and pathological factors that influence
Mandard response.
The influence of clinical parameters in tumor response
has been widely studied. In some studies, tumor size, tumor
circumferential extent, poor differentiation,mucinous tumor,
distance from anal verge, clinical T stage, nodal clinical
stage, pretreatment carcinoembryonic antigen (CEA) level,
and/or interval of time between surgery and radiotherapy
completion were associated with CRT tumor response [17–
26]. Magnetic resonance imaging (MRI) and positron emis-
sion tomography-computed tomography (PET-CT) also may
be useful to predict the response at early stages [27–33].
However, no clinical parameterswith prediction value ofCRT
response have been consistently identified. The results are
often different [19, 23, 29, 34, 35]. In our series, distance from
anal verge is the only clinical parameter in univariate analysis
with predictive value for Mandard response: distal tumors
(≤6 cm from anal verge) show a better response according
to Mandard. This result is concordant with that described
by Das et al. [18]. The opposite is described by Restivo et al.
[36].The delay of surgery after radiotherapy completion from
8 to 12 weeks seems to increase tumor necrosis grade and
pathological complete response (ypCR) rate up to 30 to 40%
[37–40]. We have 18.5% of ypCR but we cannot study this
variable because our patientswere operated on averagewithin
8 weeks after radiotherapy conclusion. Pretreatment CEA
level is probably the most cited clinical parameter as having
tumor response predictive value [18, 20, 21, 41–44]. On our
study CEA level, other clinical parameters and the biopsy
characteristics analyzed did not predict tumor response to
nCRT. Biopsy obtained data, namely, differentiation grade,
mitotic index, necrosis, inflammatory, anddesmoplastic reac-
tion amount, had no utility to recognize or predict tumor
behavior. Tumor hypoxia and proliferative cell activity reduce
the effectiveness of both radiation therapy and chemotherapy
and are a well-known risk factor for tumor radioresistance.
So, it was expected that necrosis, grade, and mitotic number
in 10 high-power fields could give any indication of CRT
tumor response. However in our series it did not occur with a
statistically significant correlation.This may be due to several
reasons. The amount of tumor in the biopsy is a very small
percentage of the total volume of the whole tumor and, as
tumors are heterogeneous, biopsy may not be representative
of tumor biology. On the other hand, it suggests that other
biologic indicators of response must be investigated, because
the ones included in this study are not important for this
purpose. Finally it must be remembered that tumor is not the
unique actor in the process; local and systemic response of
the host, immune, and inflammatory factors also need to be
considered.
In our data, all predictive factors found are one way
or another related with tumor downstaging and/or nCRT
tumor response pathological variables found after treatment.
This is an expected result. Pathological TNM stage, tumor
downstaging, and CMR of surgical specimen are reflected on
nCRT tumor response and are considered in many studies
prognostic factors of survival [45–49]. In our study the post-
treatment differentiation, feasibility, and proliferative activity
of tumor cells show greater impact as predictors of Mandard
response (more than pathological TNM stage or tumor
downstaging). The presence of accentuated necrosis, mitosis
number >9.5 for 10 high-powered fields, and moderate or
poorly differentiated grade in resected specimen had a pre-
dictive value for Mandard response of 85%. Those variables
had a significant predictive value of Mandard response in
multivariate analysis.
Thus, the only process for assessing nCRT response
is obtained from posttreatment variables. The absence of
reliable clinical predictors of response to CRT emphasizes
the need to find other factors able to predict response and
thus individualize the treatment approach in LARC. On
this series the Mandard grade response proved useful to
modify the adjuvant treatment plan in patientswhowere “bad
responders” into a more aggressive treatment.
5. Conclusions
Mandard system provides an important tool for survival
analysis. None of the clinical or the biopsy characteristics
assessed had a predictive value of Mandard response, except
the distance from anal verge. Only postoperative pathological
parameters related with tumor response to chemoradiother-
apy have predictive value for Mandard response.
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Table 5: Predictive value of clinical and pathological characteristics to Mandard response (univariate analysis).
Variables 𝑛 Bad responders % (Mandard TRG 3–5) Odds ratio 𝑝
Distance from anal verge
≤6 cm 86 58.0 1.00 0.017
>6 cm 81 39.5 2.11 (1.14–3.92)
Mitosis number in resected specimen
≤9.5 73 32.9 1.00 <0.001
≥9.6 68 77.9 7.21 (3.40–15.32)
Necrosis grade in resected specimen
Scarce 27 77.8 10.36 (3.76–28.57) <0.001
Moderate 38 92.1 34.53 (9.76–122.41) <0.001
Marked 99 25.3 1.00 <0.001
CRM distance
≥2mm 159 45.9 1.00 0.003
<2 and >1mm 8 100 2.18 (1.84–2.58)
ypT stage
0-1 38 7.9 1.00 <0.001
2–4 129 60.5 17.84 (5.21–61.09)
ypN stage
0 110 32.7 1.00
1-2 57 78.9 7.71 (3.64–16.34) <0.001
Pathological stage
0-I 58 15.5 1.00 <0.001
II 58 55.2 6.70 (2.78–16.14) <0.001
III 51 78.4 19.80 (7.47–52.48) <0.001
T downstaging
Yes 67 23.9 1.00 <0.001
No 100 65.0 5.92
Pathological TNM downstaging
Yes 96 34.4 1.00 <0.001
No 70 67.1 3.90
Reduction of mitosis number
Yes 83 41.0 1.00 <0.001
No 52 73.1 3.91 (1.84–8.30)
Differentiation grade in resected specimen
0 + 1 52 15.4 1.00 <0.001
2 + 3 115 63.5 9.56
Table 6: Multivariate stepwise model-dependent variable Mandard response: “0” good response and “1” bad response.
Variable Odds ratio Confidence interval 95% 𝑝
Differentiation grade in resected specimen
0 + 1 1.00 3.38–32.30 <0.001
2 + 3 10.45
Necrosis grade in resected specimen
Marked 1.00 3.04–25.54 <0.001
Scarce/moderate 8.82
Mitosis number in resected specimen
≤9.5 1.00 1.52–10.90 0.005
≥9.6 4.07
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Based on these results it is not yet possible to identify the
group of patients who truly benefits from neoadjuvant CRT,
but we can identify the group of patients (the Mandard bad
responders) that will benefit with a more aggressive adjuvant
treatment.
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